Soligenix, Inc. (SNGX) surged 92.15 percent to $5.34, up $2.56 on Monday, after announcing that the FDA granted orphan drug designation to dusquetide, the active ingredient in SGX945, for the treatment of Behçet's Disease. The decision follows encouraging Phase 2a trial results showing biological efficacy and safety in patients. The stock opened at $3.79 and traded between $3.57 and $6.23, with volume spiking to 169.53 million shares, far above its average of 8.06 million on the Nasdaq. Soligenix's 52-week range is between $1.09 and $6.23.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.